Characteristics and antimicrobial therapy of bloodstream infections in tumour patients with special reference to antibiotic stewardship.

IF 2.7 3区 医学 Q3 ONCOLOGY
Jiri Rejthar, Maximilian Desole, Andrea Stroux, Pierre Kremer, Lars Geerdts, Anna Kopf, Madlen Löbel, Joanna Lasocka, Heidrun Peltroche-Llacsahuanga, Martin Schmidt-Hieber
{"title":"Characteristics and antimicrobial therapy of bloodstream infections in tumour patients with special reference to antibiotic stewardship.","authors":"Jiri Rejthar, Maximilian Desole, Andrea Stroux, Pierre Kremer, Lars Geerdts, Anna Kopf, Madlen Löbel, Joanna Lasocka, Heidrun Peltroche-Llacsahuanga, Martin Schmidt-Hieber","doi":"10.1007/s00432-025-06204-y","DOIUrl":null,"url":null,"abstract":"<p><p>Bloodstream infections (BSI) are among the most frequent infections in tumour patients. We analysed 123 tumour patients (105 retrospective, 18 prospective) with BSI. The most common underlying tumour diseases were acute leukaemia/myelodysplastic syndrome (40%), followed by lymphomas (25%) and multiple myeloma (20%). BSI were more frequently caused by Gram-negative than Gram-positive bacteria (53% vs. 40%), including Escherichia coli (33%), coagulase-negative Staphylococcus spp. (14%), and Pseudomonas aeruginosa (10%). The median time to fever resolution was 3 days (range 1-30 days). Neither pathogen type, initial antibiotic treatment, nor key patient characteristics significantly affected fever resolution time. Non-susceptibility of the pathogen to empirical antibiotic treatment was linked to prolonged fever resolution (HR 0.53, 95%-CI 0.28-1.0, p = 0.04). The severity of neutropenia on admission had a significant impact on 60-day survival (HR 2.95, 95%-CI 1.10-7.93, p = 0.03). In contrast, such an effect on survival was not observed by the non-susceptibility of the pathogen to primary empirical antibiotic treatment (HR 2.12, 95%-CI 0.71-6.30, p = 0.18). Non-adherence or questionable adherence to antibiotic stewardship (ABS) recommendations (n = 42, 34%) correlated with delayed fever resolution (median 3 days vs. 4 days; p = 0.04) and was more frequent in retrospectively than in prospectively recorded patients (38% vs. 11%, p = 0.03). Gram-negative bacteria still predominate as BSI agents in tumour patients. Prospective evaluation of anti-infective management may enhance adherence to ABS recommendations.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 4","pages":"152"},"PeriodicalIF":2.7000,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12034589/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Research and Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00432-025-06204-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Bloodstream infections (BSI) are among the most frequent infections in tumour patients. We analysed 123 tumour patients (105 retrospective, 18 prospective) with BSI. The most common underlying tumour diseases were acute leukaemia/myelodysplastic syndrome (40%), followed by lymphomas (25%) and multiple myeloma (20%). BSI were more frequently caused by Gram-negative than Gram-positive bacteria (53% vs. 40%), including Escherichia coli (33%), coagulase-negative Staphylococcus spp. (14%), and Pseudomonas aeruginosa (10%). The median time to fever resolution was 3 days (range 1-30 days). Neither pathogen type, initial antibiotic treatment, nor key patient characteristics significantly affected fever resolution time. Non-susceptibility of the pathogen to empirical antibiotic treatment was linked to prolonged fever resolution (HR 0.53, 95%-CI 0.28-1.0, p = 0.04). The severity of neutropenia on admission had a significant impact on 60-day survival (HR 2.95, 95%-CI 1.10-7.93, p = 0.03). In contrast, such an effect on survival was not observed by the non-susceptibility of the pathogen to primary empirical antibiotic treatment (HR 2.12, 95%-CI 0.71-6.30, p = 0.18). Non-adherence or questionable adherence to antibiotic stewardship (ABS) recommendations (n = 42, 34%) correlated with delayed fever resolution (median 3 days vs. 4 days; p = 0.04) and was more frequent in retrospectively than in prospectively recorded patients (38% vs. 11%, p = 0.03). Gram-negative bacteria still predominate as BSI agents in tumour patients. Prospective evaluation of anti-infective management may enhance adherence to ABS recommendations.

肿瘤患者血流感染的特点和抗菌治疗,特别涉及抗生素管理。
血流感染(BSI)是肿瘤患者最常见的感染之一。我们分析了123例BSI患者(105例回顾性,18例前瞻性)。最常见的潜在肿瘤疾病是急性白血病/骨髓增生异常综合征(40%),其次是淋巴瘤(25%)和多发性骨髓瘤(20%)。革兰氏阴性菌比革兰氏阳性菌更常引起BSI(53%比40%),包括大肠杆菌(33%)、凝固酶阴性葡萄球菌(14%)和铜绿假单胞菌(10%)。发热消退的中位时间为3天(范围1-30天)。病原体类型、初始抗生素治疗和关键患者特征均未显著影响发热消退时间。病原体对经验性抗生素治疗不敏感与发热消退时间延长有关(HR 0.53, 95%-CI 0.28-1.0, p = 0.04)。入院时中性粒细胞减少的严重程度对60天生存率有显著影响(HR 2.95, 95%-CI 1.10-7.93, p = 0.03)。相比之下,病原菌对初级经验性抗生素治疗不敏感并未观察到这种对生存的影响(HR 2.12, 95%-CI 0.71-6.30, p = 0.18)。不遵守或可疑地遵守抗生素管理(ABS)建议(n = 42,34%)与延迟发烧消退相关(中位3天vs. 4天;P = 0.04),并且回顾性记录的患者比前瞻性记录的患者更常见(38%对11%,P = 0.03)。革兰氏阴性菌在肿瘤患者中仍占主导地位。抗感染管理的前瞻性评价可能会加强对ABS建议的遵守。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.00
自引率
2.80%
发文量
577
审稿时长
2 months
期刊介绍: The "Journal of Cancer Research and Clinical Oncology" publishes significant and up-to-date articles within the fields of experimental and clinical oncology. The journal, which is chiefly devoted to Original papers, also includes Reviews as well as Editorials and Guest editorials on current, controversial topics. The section Letters to the editors provides a forum for a rapid exchange of comments and information concerning previously published papers and topics of current interest. Meeting reports provide current information on the latest results presented at important congresses. The following fields are covered: carcinogenesis - etiology, mechanisms; molecular biology; recent developments in tumor therapy; general diagnosis; laboratory diagnosis; diagnostic and experimental pathology; oncologic surgery; and epidemiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信